Trials / Research
(Download Trials / Research)

1. Principal Investigator;"A Multicenter Comparison of the Safety and
Efficacy of Lomefloxacin vs. Ofloxacin in the treatment of Bacterial Prostatitis Protocol #S69-91-02-196
G.D. Searle & Co.

2. Principal Investigator;"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Investigate the Long-Term Effects of Finasterde (MK- 906) in Patients with Benign Prostatic Hyperplasia." Protocol 048- 04/GHBA-909 - Merck Research Laboratories/G.H. Besselaar Associates.

3. Principal Investigator;"A Phase II Dose Ranging Efficacy Study of Oral Zanoterone, A New Steroidal Androgen Receptor Antagonist, In Men with Symptomatic Benign Prostatic Hyperplasia" Protocol #49596-005- Sterling Drug Co.

4. Principal Investigator; " A Phase II dose Ranging Safety and Efficacy Study of Oral Zanoterone in Subjects with Stage D2 Carcinoma of the Prostate," Protocol #49596-204 - Theradex/Sterling Winthrop Pharmaceuticals.

5. Principal Investigator;"Doxazosin vs. Placebo in the management of symptomatic B.P.H." A double-blind placebo-controlled long term study with a long-term open label branch. Pfizer Inc.

6. Principal Investigator; "A One-Year, Multicenter, double-Blind Comparison of the effects of SKF 105657 vs. Placebo in the treatment of symptomatic B.P.H. With Six Month Untreated Follow-Up," Protocol 105657/018 - Smith Kline Beecham Pharmaceuticals.

7. Principal Investigator;"A Randomized Double-Blind Placebo-Controlled Parallel Study to Assess the Efficacy and Safety of Four Dose Levels of RS-15385 in Men with Erectile Disorder." Protocol #92CE28-0606 - Syntex Development Corp.

8. Principal Investigator; "A Twenty-Six Week , Double-Blind, Placebo- Controlled Parallel Study With an Open-Label Extension Using Doxazosin Tablets for the Treatment of Benign Prostatic Hyperplasia," Protocol #92CE28-0606 -Pfizer Central Research, Inc.

9. Principal Investigator; "A Randomized Pilot Study to Assess the Efficacy and Safety of Two Oral Dose Levels of Delaquamine HCl in Men With Erectile Disorder.." Protocol #DELS2282-Syntex Development Research.

10. Principal Investigator; "A Phase II Dose Finding Placebo Controlled Study of Four Dose Levels of YM617 in Patients with Signs and Symptoms of Benign Prostatic Hyperplasia." Protocol #YM617US90-01 - Yamanouchi Pharmaceutical Company L\, Ltd./Oxford Research International Corporation.

11. Principal Investigator; "Ro 23-6240 (Fleroxacin) in Uncomplicated Urinary Infections in Women.A Randomized, double Blind, Prospective Study Versus Ciprofloxacin" Protocol #N3606B, Hoffman-LaRoche

12. Principal Investigator; "A Sixteen-Week, Double-Blind, Placebo-Controlled Dose Response Study Using Doxazosin Tablets For the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients," Protocol #90CE28-0488 Pfizer, Inc. New York.

13. Principal Investigator; "A Phase II/III Open-Label, Long-Term, Follow-up Safety Study of Oral Zanoterone in Men with Symptomatic Benign Prostatic Hyperplasia." Protocol #49496-006 - Sterling Winthrop Pharmaceuticals Research Division.

14. Principal Investigator; "A One-Year Multicenter, Double-Blind Comparison of the Effects of Once-Daily Dosing with Three Dose Levels of SK&F 105657 or Placebo in the Treatment of Symptomatic Benign Prostatic Hyperplasia with Six-Month Untreated Follow-up," Protocol # 15385S2280 Syntex Development Research.

15. Principal Investigator; "A Two-Year, Open-Label, Multicenter Study of Oral Epristeride 80mg.Once Daily in the Treatment of Benign Prostatic Hyperplasia," Protocol #10560/051 - SmithKline Beecham ` Pharmaceuticals.

16. Principal Investigator; "A One-Year, Open Label, Multicenter Study of Oral Epristeride 80mg. Once Daily in the Treatment of Benign Prostatic Hyperplasia," Protocol #105657/051 - SmithKline Beecham Pharmaceuticals.

17. Principal Investigator;Part A - "Clinical Efficacy and Safety of Two Doses of Tolterodine Compared to Placebo, A Phase III Randomized, Double Blind, Multinational Study in Patients With Detrusor Over-Activity and Symptoms of Frequency, Urge Incontinence and Urgency." Part B - Long-Term Safety, Tolerability and Clinical Efficacy of Tolterodine-A phase III, Open, Multinational Study in Patients with Detrusor Over-Activity nd Symptoms of Frequency, Urge Incontinence, and Urgency." Protocol 940ATA009- 923, Pharmacia, Inc.

18. Principal Investigator; A Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Evaluation of GII98745 and Finasteride in Subjects with Benign Prostatic Hyperplasia" Protocol #ARIA2001, Glaxo Wellcome, Inc.

19. Principal Investigator; "A Five-Month, double Blind, Placebo-Controlled, Randomized Multicenter Cross-Over Study of the Effects and Safety of Testosterone Transdermal System (TTD System) in Men Presenting with Sexual Dysfunction and Serum Testosterone Levels <350ng./dl/" Protocol #TT1000/002
SmithKline Beecham Pharmaceuticals/Clin Trials, Inc.

20. Principal Investigator; "A Double-Blind, Randomized, Placebo-Controlled Parallel Group, Multicenter, Flexible Dose Escalation Study to Assess the Efficacy and Safety of Sildenafil Administered as Required to Male Patients with Erectile Dysfunction" Protocol #148-103 (CBI-1171) Pfizer/Corning Bessalaar.

21. Principal Investigator; "A Double-Blind, Placebo-Controlled, dose-Ranging Clinical Evaluation of G1231818 In Subjects with Benign Prostatic Hyperplasia" Protocol #A1A2001,, Glaxo Wellcome Inc/Clin Trials Research, Inc.

22. Principal Investigator; "A Phase III Efficacy and safety Study of Three Fixed doses of Apomorphine SL Tablets Versus Placebo in the treatment of Male Erectile Dysfunction" M96-470, Tap Holdings./IBRD-Rostrum Global.

23. Principal Investigator; "The Maximum Tolerated and Minimum Effective Dose of OROS* in the Treatment of Patients with Urge or Mixed Urinary Incontinence."
C95-049-02, ALZA Corporation.

24. Principal Investigator; "A Double-Blind, Placebo-Controlled Crossover Design Study to Evaluate the Effects of Three Single Doses of a Selective Alpha-1 Adrenoreceptor Antagonis RS-100975-190 on Peak Urinary Flow Rate in Men with Benign Prostatic Hyperplasia (BPH)" S2679 - Roche
Bioscience.

25. Principal Investigator; "A Double-Blind, Placebo Controlled, Parallel, Fixed
Dose Study of Sertraline In The Management of Premature Ejaculation.
Protocol 96CE21-0702 Pfizer Pharmaceuticals

26. Principal Investigator; Prospective Study for Urethrin Implant used in the Treatment of Urinary Incontinence. Protocl G930198. Mentor Urology

27. Principal Investigator; Evaluation of the Safety and Efficacy of MUSE plus the ACTIS Venous Flow Controller in Men with Erectile Dysfunction.
Protocol AV-01. Vivus, Inc. Menlo Park, CA

28. Principal Investigator; An Open-Label trial of Oral Phentolamine in Patients with Mild to Moderate Erectile Dysfunction. Protocol ZON 303
Zonagen, Inc. The Woodlands, Texas

29. Principal Investigator: A prospective Study of Mentor Alpha-1 Penile
Implant in Men with Organic Impotence.
Mentor Urology. Santa Barbara CA

30. Principal Investigator: A Prospective Study of the Efficacy and Reliability of the DP9010 Inflatable Penile Prosthesis. A Phase III
Study.
American Medical Systems. Minnetonka MN

31. Principal Investigator: A Phase III Efficacy and Safety Study Comparing
Escalating Doses of Apomorphine SL to 5 or 6 mg. Doses of Apomorphine SL or Placebo in the Treatment of Male Erectile
Dysfunction. Protocol Number M97-763
Tap Holdings, Inc.

32. Principal Investigator; Benign Prostatic Hyperplasia (BPH): Effectiveness
of Terazosin Therapy in Patients Treated With Finasteride.
Abbott/SCP

33. Principal Investigator: Duloxetine versus placebo in the relief of stress
incontinence. Protocol FIJ-MC-SAAW(a) Eli Lilly Inc.

34. Principal Investigator: Efficacy and Safety of Alfuzosin Once Dail Tablets at Two dosage Levels Versus Placebo In Patients With Symptomatic Benign Prostatic Hyperplasia. Protocol 2650. Synthelabo.

35. Principal Investigator: A Randomized, Double-blind Comparative trial
Of Biclutamide 150mg. Versus Placebo Each in Combination with
Castration as Second-line Therapy in Patients with Asymptomatic
Metastatic Prostate Cancer. Protocol 7054US/0007 Zeneca Pharmaceuticals.

36. Prinicpal Investigator: A Dose-Range Finding Double-Blind, Randomized, Placebo-controlled, Multicenter, Active Comparator Study to Determing the Effect of L-753099 in Postmenopausal Women with Predominately Urge Urinary Incontinence. Protocol 011-00Draft. Merck Research Laboratories.
37. Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Fixed-dose, Dose-Ranging Study to Assess the Safety and Efficacy of Daily Administration of a Single Oral Dose of YM905 in male and Female Patients with Urge Urinary Incontinence. Protocol 905-CL-006. Yamanouchi USA, Inc.

38. Principal Investigator: Long term Compliance of Oral Supplements by Oncology Outpatients in Need of Nutritional Support. Project 7081 Protocol 9912. Mead Johnson Nutritionals

39. Prinicipal Investigator: A Study on Incidence of Autoinflation with the American Medical Systems 700 Series Inflatable Penile Prosthesis.
Protocol AMS99-003. American Medical Systems.

40. Principal Investigator: A randomized, double-blind, placebo-controlled, multi-center, fixed dose, parallel group, 3-month comparison study to investigate the efficacy and safety of the phosphodiesterase Type V inhibitor BAY 38-9456 in males with erectile dysfunction and diabetes mellitus. Bayer Pharmaceutical Divison. West Haven CT

41. Principal Investigator: Double-blind, randomized, placebo-controlled, parallel group study of the efficacy and safety of darifenacin versus tolterodine in the treatment of subjects with overactive bladder. Protocol A1371001 Pfizer Pharmaceuticals, NY

42. Sub-Investigator: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing Oxybutinin Transdermal Systems versus Tolterodine Long-Acting Capsules in Patients with Overactive Bladder. Protocol O00011, Watson Pharmaceuticals. Salt Lake City UT

43. Principal Investigator: A Randomized, Placebo-Controlled, Double-Blind, Parallel Design, Phase 3 Trial of the Efficacy and safety of Alprox-TD in Male Patients with Erectile Dysfunction. Protocol No MED 2000-DDS
NexMed, Inc.

44.Principal Investigator; Protocol FIJ-MC-SBAY Long Term Monitoring of Safety in Subjects Treated with Duloxetene for Stress Urinary Incontinence. Lilly Pharmaceuticals. Indianapolis, IN.

45. Principal Investigator; Trial 526.26, A two phase, double blinded, randomized, parallel group design, multicenter study of Flomax capsules, 0.4 mg. Versus placebo in male pateints with acute urinary retention related to benign prostatic hyperplasia. Boehringer Ingelhem, Inc.

46. Principal Investigator, A 6-Week, Double-Blind, Placebo Controlled, Randomized, Parallel Group, Multicenter, Multidose Study of the Efficacy and safety of KW-7158 in Patients with Overactive Bladder Symptoms of Increased Urinary Frequency, Urgency and Urge Incontinence. Study 71580INT-001. Kyowa Pharmaceutical, Inc.

47. Principal Investigator, A Double-Blind, Rnadomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Rofecoxib in Decreasing the Risk of Prostate Cancer. Protocol MK-0966-201. Merck, Inc.

48. Principal Investigator; A Randomized, Placebo-Controlled, Parallel Group Study of the efficacy and safety of Dutasteride 0.5 mg. Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer. The REDUCE Trial. Protocol ARI4006.

49. Principal Investigator; A randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and reliability of 20mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and a demonstrated successful first response to 20mg vardenafil.Study #BAY38-9456/100497. Bayer

50. Principal Investigator; A double blind, placebo controlled, randomized US/Latin America study to evaluate the effect of tolterodine prolonged release on nocturia in patients with symptoms of overactive bladder. Protocol 583E-URO-0084-037, IND#56,406. Pfizer/Pharmacia

51. Principal Investigator; A six month open label, randominzed multi-center study to evaluate the comparative efficacy and safety of oral Famvir in the episodic and suppressive treatment of recurrent genital herpes. Protocol CFAM810A US07, Novartis Pharmaceuticals.

52. Principal Investigator; A Multi-center, double-blind, Randomized, Active-Controlled Parallel Group Study to Evaluate the Lipid-altering Efficacy of MK-0767 in Patients with Type 2 Diabetes and Dyslipidemia. Protocol 034; Merck Inc.

53. Principal Investigator; A Multicenter, Open Label, Flexible Dose Study To Investigate the Use of Patterns of Viagra (sildenafil citrate) and the Ability of Investigators to Further Optimize Subject Satisfaction with Viagra Through Customized Instruction. Protocol A1481179, Pfizer, Inc.

54. Principal Investigator; A Multi-center, Double-blind, Randomized, Active Controlled Parallel Study in Patients with Type 2 Diabetes to Evaluate the Cardiac and Metabolic Effects of MK-0767. Merck Pharmaceuticals Inc.

55. Principal Investigator; Open Label Study on the Safety and Efficacy of 5 and 10 mg Vesicare in Patients with Overactive Bladder Symptoms. Protocol 905-UC-001 Yamanouchi Pharma America, Inc.

56. Principal Investigator; A Randmomized, double-blind, Multicenter, Placebo-controlled, Parallel group study to Evaluate the Efficacy and Safety of Valsartan (320mg.) and Hydrochlorthiazide (12.5 and 25mg) combined and alone, Valsartan 160 mg. and Valsartan 160 mg/Hydrochorthiazed 12.5 mg in Hypertensive Patients. Study No CVAH631C2301. Novartis Pharmaceuticals Corporation

57. Principal Investigator; Study of Duloxetine DCl in women of Different Demographic characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety. Protocol F1J-US-SBCD. Eli Lilly & Co.

58. Princiapl Investigator; An Open-Label stuidy to Evaluate the Efficacy and Safety of Tadalafil Aministered “On Demand” to Men of Various Populations with Erectile Dysfunction. Protocol No.: H6D-MC-LVFN(b) Lilly, ICOS LLC.